Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS-Mutant non-small cell lung cancer: From biology to therapy

20 Jul 2018

Abstract excerpt

In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and KRAS-mutant NSCLC is associated with smoking. There are various sources of biological heterogeneity of KRAS-mutant NSCLC, including different genotypes that may be associated with specific clinical outcomes, the presence of other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Treatments and Mutations
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30268480
DOI: 10.1016/j.lungcan.2018.07.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS-Mutant non-small cell lung cancer: From biology to therapyPMID 30268480Read ↗

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.Semantic proximity Read ↗

Treating KRAS -mutant NSCLC: latest evidence and clinical consequencesSemantic proximity Read ↗

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

New Horizons in KRAS-Mutant Lung Cancer: Dawn After DarknessSemantic proximity Read ↗

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung CancersSemantic proximity Read ↗

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read ↗

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.Semantic proximity Read ↗

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibitionSemantic proximity Read ↗

KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSemantic proximity Read ↗

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and RestrictionsSemantic proximity Read ↗

Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.